Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$7 Mln
P/E Ratio
--
P/B Ratio
1.76
Industry P/E
--
Debt to Equity
0.02
ROE
-1.88 %
ROCE
-184.54 %
Div. Yield
0 %
Book Value
0.44
EPS
-1.67
CFO
$-70.14 Mln
EBITDA
$-76.70 Mln
Net Profit
$-88.02 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Indaptus Therapeutics (INDP)
| -44.79 | -38.44 | -44.79 | -80.30 | -48.62 | -52.42 | -- |
|
BSE Sensex
| 1.48 | 4.01 | 3.03 | 8.65 | 11.66 | 20.20 | 11.03 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Indaptus Therapeutics (INDP)
| -51.87 | 21.38 | -74.56 | -58.70 | -65.50 | -93.37 | 46.10 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 35.59 | 9,973.38 | 20.56 | 23.13 | |
| 288.99 | 8,956.07 | 23.48 | 58.42 | |
| 25.13 | 9,555.39 | -- | -28.77 | |
| 100.68 | 10,030.35 | 30.81 | 14.16 |
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination... therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. Address: Three Columbus Circle, New York, NY, United States, 10019 Read more
CEO & Director
Mr. Jeffrey A. Meckler
Founder, Chief Scientific Officer & Director
Dr. Michael J. Newman Ph.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Indaptus Therapeutics Inc (INDP) stood at $ 7 Mln as on 31-Dec-24
The share price of Indaptus Therapeutics Inc (INDP) is $0.46 (NASDAQ) as of 21-Apr-2025 16:00 EDT. Indaptus Therapeutics Inc (INDP) has given a return of -48.62% in the last 3 years.
Indaptus Therapeutics Inc (INDP) has a market capitalisation of $ 7 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Indaptus Therapeutics Inc (INDP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Indaptus Therapeutics Inc (INDP) and enter the required number of quantities and click on buy to purchase the shares of Indaptus Therapeutics Inc (INDP).
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. Address: Three Columbus Circle, New York, NY, United States, 10019
The CEO & director of Mr. Jeffrey A. Meckler. is Indaptus Therapeutics Inc (INDP), and CFO & Sr. VP is Dr. Michael J. Newman Ph.D..
There is no promoter pledging in Indaptus Therapeutics Inc (INDP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Indaptus Therapeutics Inc. (INDP) | Ratios |
|---|---|
|
Return on equity(%)
|
-187.52
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Indaptus Therapeutics Inc (INDP) was $0 Mln.
$-0.02
(
